MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Alvotech SA

Abierto

SectorSanidad

8.02 -2.31

Resumen

Variación precio

24h

Actual

Mínimo

8.06

Máximo

8.44

Métricas clave

By Trading Economics

Ingresos

-56M

-67M

Ventas

48M

151M

BPA

-0.24

Margen de beneficios

-44.289

Empleados

1,012

EBITDA

-258M

-120M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+139.23% upside

Dividendos

By Dow Jones

Próximas Ganancias

20 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-976M

2.5B

Apertura anterior

10.33

Cierre anterior

8.02

Alvotech SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 abr 2025, 14:54 UTC

Ganancias

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

7 may 2024, 20:30 UTC

Principales Noticias

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Comparación entre iguales

Cambio de precio

Alvotech SA previsión

Precio Objetivo

By TipRanks

139.23% repunte

Estimación a 12 Meses

Media 20 USD  139.23%

Máximo 28 USD

Mínimo 14 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alvotech SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.